FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.21  |  FHIR Version n/a  User: [n/a]

34762411000001100: MagnaPhos 97.2mg/5ml (4mmol/5ml) oral solution (TriOn Pharma Ltd) (product)

Status: current, Not sufficiently defined by necessary conditions definition status. Date: 11-Oct 2017. Module: SNOMED CT United Kingdom drug extension module

Descriptions:

Id Description Lang Type Status Case? Module
105096101000001112 MagnaPhos 97.2mg/5ml (4mmol/5ml) oral solution (TriOn Pharma Ltd) (product) en Fully specified name Active Entire term case sensitive SNOMED CT United Kingdom drug extension module
105096201000001117 MagnaPhos 97.2mg/5ml (4mmol/5ml) oral solution (TriOn Pharma Ltd) en Synonym Active Entire term case sensitive SNOMED CT United Kingdom drug extension module

0 descendants.

Expanded Value Set

Outbound Relationships Type Target Active Characteristic Refinability Group Values
MagnaPhos 97.2mg/5ml (4mmol/5ml) oral solution (TriOn Pharma Ltd) Has NHS dm+d (dictionary of medicines and devices) basis of strength substance Magnesium true Inferred relationship Existential restriction modifier
MagnaPhos 97.2mg/5ml (4mmol/5ml) oral solution (TriOn Pharma Ltd) Has NHS dm+d (dictionary of medicines and devices) controlled drug category Controlled drug category No Controlled Drug Status true Inferred relationship Existential restriction modifier
MagnaPhos 97.2mg/5ml (4mmol/5ml) oral solution (TriOn Pharma Ltd) Has NHS dm+d (dictionary of medicines and devices) AMP (actual medicinal product) availability restriction indicator NHS dm+d (dictionary of medicines and devices) AMP (actual medicinal product) availability restriction none true Inferred relationship Existential restriction modifier
MagnaPhos 97.2mg/5ml (4mmol/5ml) oral solution (TriOn Pharma Ltd) Is a Magnesium glycerophosphate 97.2mg/5ml oral solution true Inferred relationship Existential restriction modifier
MagnaPhos 97.2mg/5ml (4mmol/5ml) oral solution (TriOn Pharma Ltd) Has active ingredient Magnesium glycerophosphate true Inferred relationship Existential restriction modifier
MagnaPhos 97.2mg/5ml (4mmol/5ml) oral solution (TriOn Pharma Ltd) Has manufactured dose form Conventional release oral solution true Inferred relationship Existential restriction modifier
MagnaPhos 97.2mg/5ml (4mmol/5ml) oral solution (TriOn Pharma Ltd) Has basis of strength substance Magnesium true Inferred relationship Existential restriction modifier
MagnaPhos 97.2mg/5ml (4mmol/5ml) oral solution (TriOn Pharma Ltd) VMP prescribing status (attribute) VMP valid as a prescribable product true Inferred relationship Existential restriction modifier
MagnaPhos 97.2mg/5ml (4mmol/5ml) oral solution (TriOn Pharma Ltd) VMP non-availability indicator Available true Inferred relationship Existential restriction modifier
MagnaPhos 97.2mg/5ml (4mmol/5ml) oral solution (TriOn Pharma Ltd) Has specific active ingredient Magnesium glycerophosphate true Inferred relationship Existential restriction modifier
MagnaPhos 97.2mg/5ml (4mmol/5ml) oral solution (TriOn Pharma Ltd) Has dispensed dose form Conventional release oral solution true Inferred relationship Existential restriction modifier
MagnaPhos 97.2mg/5ml (4mmol/5ml) oral solution (TriOn Pharma Ltd) Has excipient Excipient not declared true Inferred relationship Existential restriction modifier
MagnaPhos 97.2mg/5ml (4mmol/5ml) oral solution (TriOn Pharma Ltd) Is a Actual medicinal product true Inferred relationship Existential restriction modifier
MagnaPhos 97.2mg/5ml (4mmol/5ml) oral solution (TriOn Pharma Ltd) Is a MagnaPhos true Inferred relationship Existential restriction modifier
Inbound Relationships Type Active Source Characteristic Refinability Group
MagnaPhos 97.2mg/5ml (4mmol/5ml) oral solution (TriOn Pharma Ltd) 200 ml Has AMP True MagnaPhos 97.2mg/5ml (4mmol/5ml) oral solution (TriOn Pharma Ltd) Inferred relationship Existential restriction modifier

This concept is not in any reference sets

Back to Start